Donald Craig Simonson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Donald Craig Simonson has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Mary-Elizabeth Patti
Joslin Diabetes Center, Harvard Medical School Boston Massachusetts USA
10 shared publications Ashley H. Vernon
Brigham and Women’s Hospital, Boston, MA
5 shared publicationsBo Hu
Duke University School of Medicine, Durham, NC
5 shared publicationsDavid E. Cummings
University of Washington Medical School, Seattle, WA
5 shared publicationsPhilip R. Schauer
Pennington Biomedical Research Center, Baton Rouge, LA
5 shared publicationsWilliam F. Gourash
10University of Pittsburgh Medical Center, Pittsburgh, PA
5 shared publications
Latest Publications
- 20 October 2026
- Published by American Diabetes Association in Diabetes Care
Predictors of Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery or Medical-Lifestyle Therapy in the ARMMS-T2D Study
OBJECTIVE: Metabolic-bariatric surgery (MBS) is effective in promoting remission of type 2 diabetes, but this outcome is not universally achieved. We identified baseline patient characteristics that predict diabetes remission and subsequent relapse after various MBS procedures versus intensive medical-lifestyle intervention. RESEARCH DESIGN AND METHODS: Alliance of Randomized Trials of Medicine vs. Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) is a 14-year, multicenter study of health outcomes in 262 patients with type 2 diabetes (68% women, age 49.9 ± 8.3 years, BMI 36.4 ± 3.5 kg/m2, HbA1c 8.5 ± 1.5%) previously randomized to MBS (n = 166) or medical-lifestyle management (n = 96). Predictors of remission (defined as HbA1c <6.5% on no glucose-lowering medications) and relapse were determined using univariate time-to-event analyses of prespecified candidate predictors plus agnostic, multivariate least absolute shrinkage and selection operator. RESULTS: Throughout a median of 11 years (maximum 14 years) of follow-up, 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management. Predictors of diabetes remission in univariate analyses included shorter diabetes duration, no insulin use, fewer glucose-lowering medication classes used, greater body weight, higher fasting C-peptide and insulin levels, and weight loss at 1 year (all P < 0.05). Diabetes remission predictors in multivariate analyses included baseline diabetes duration, insulin use, and weight change at 1 year (all P < 0.01). Diabetes relapse after initial remission in the MBS group was predicted by longer baseline diabetes duration and greater number of glucose-lowering medication classes used. CONCLUSIONS: Baseline predictors of diabetes remission and subsequent relapse among participants randomized to one of three MBS procedures or a medical-lifestyle intervention should help inform personalized selection of diabetes treatment.
- 20 October 2026
- Published by American Diabetes Association in Diabetes Care
Predictors of Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery or Medical-Lifestyle Therapy in the ARMMS-T2D Study
OBJECTIVE: Metabolic-bariatric surgery (MBS) is effective in promoting remission of type 2 diabetes, but this outcome is not universally achieved. We identified baseline patient characteristics that predict diabetes remission and subsequent relapse after various MBS procedures versus intensive medical-lifestyle intervention. RESEARCH DESIGN AND METHODS: Alliance of Randomized Trials of Medicine vs. Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) is a 14-year, multicenter study of health outcomes in 262 patients with type 2 diabetes (68% women, age 49.9 ± 8.3 years, BMI 36.4 ± 3.5 kg/m2, HbA1c 8.5 ± 1.5%) previously randomized to MBS (n = 166) or medical-lifestyle management (n = 96). Predictors of remission (defined as HbA1c <6.5% on no glucose-lowering medications) and relapse were determined using univariate time-to-event analyses of prespecified candidate predictors plus agnostic, multivariate least absolute shrinkage and selection operator. RESULTS: Throughout a median of 11 years (maximum 14 years) of follow-up, 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management. Predictors of diabetes remission in univariate analyses included shorter diabetes duration, no insulin use, fewer glucose-lowering medication classes used, greater body weight, higher fasting C-peptide and insulin levels, and weight loss at 1 year (all P < 0.05). Diabetes remission predictors in multivariate analyses included baseline diabetes duration, insulin use, and weight change at 1 year (all P < 0.01). Diabetes relapse after initial remission in the MBS group was predicted by longer baseline diabetes duration and greater number of glucose-lowering medication classes used. CONCLUSIONS: Baseline predictors of diabetes remission and subsequent relapse among participants randomized to one of three MBS procedures or a medical-lifestyle intervention should help inform personalized selection of diabetes treatment.
- 1 March 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (3) , 353-361
Effect of Social Vulnerability on Efficacy of Bariatric Surgery Versus Medical and Lifestyle Intervention for Type 2 Diabetes: Analysis of the ARMMS-T2D Consortium of Randomized Trials
Social determinants of health (SDOH) can affect metabolic health. To determine the effect of social vulnerability on the comparative effectiveness of metabolic bariatric surgery or medical and lifestyle intervention on glycemia and weight outcomes in people with type 2 diabetes (T2D). Analysis of the effect modification of baseline Area Deprivation Index (ADI; a metric of social vulnerability) on longitudinal outcomes between randomized treatment groups using linear mixed-effects models. (ClinicalTrials.gov: NCT02328599). 4 U.S. academic centers. 258 participants with T2D enrolled in 4 randomized controlled trials of surgical versus medical management and a longitudinal observational follow-up study. ADI linked to ZIP code data at randomization; weight loss and hemoglobin A1c (HbA1c) level at the end of the active intervention period (7 to 12 years). Baseline characteristics were well balanced between the surgical and medical therapy groups after adjustment for study site and stratification by high versus low ADI. Surgery was more effective than medical therapy in reducing HbA1c level among persons with high ADI (net difference, -1.29% [95% CI, -1.95% to -0.63%]) and those with low ADI (net difference, -0.95% [CI, -1.29% to -0.62%]). Surgery was also more effective than medical therapy at producing weight loss across ADIs, with respective net differences of -10.6% (CI, -15.2% to -5.9%) for high ADI and -13.3% (CI, -15.7% to -10.9%) for low ADI. The interaction between ADI and intervention group was not significant for either HbA1c (P = 0.37) or weight loss (P = 0.31). Small sample size; parent trials were not designed to address effect modification by ADI. Surgery was superior to medical therapy for people with T2D regardless of social deprivation. This study did not detect statistically significant differences in the comparative advantage of surgery over medical therapy by ADI. National Institutes of Health.
- 1 March 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (3) , 353-361
Effect of Social Vulnerability on Efficacy of Bariatric Surgery Versus Medical and Lifestyle Intervention for Type 2 Diabetes: Analysis of the ARMMS-T2D Consortium of Randomized Trials
Social determinants of health (SDOH) can affect metabolic health. To determine the effect of social vulnerability on the comparative effectiveness of metabolic bariatric surgery or medical and lifestyle intervention on glycemia and weight outcomes in people with type 2 diabetes (T2D). Analysis of the effect modification of baseline Area Deprivation Index (ADI; a metric of social vulnerability) on longitudinal outcomes between randomized treatment groups using linear mixed-effects models. (ClinicalTrials.gov: NCT02328599). 4 U.S. academic centers. 258 participants with T2D enrolled in 4 randomized controlled trials of surgical versus medical management and a longitudinal observational follow-up study. ADI linked to ZIP code data at randomization; weight loss and hemoglobin A1c (HbA1c) level at the end of the active intervention period (7 to 12 years). Baseline characteristics were well balanced between the surgical and medical therapy groups after adjustment for study site and stratification by high versus low ADI. Surgery was more effective than medical therapy in reducing HbA1c level among persons with high ADI (net difference, -1.29% [95% CI, -1.95% to -0.63%]) and those with low ADI (net difference, -0.95% [CI, -1.29% to -0.62%]). Surgery was also more effective than medical therapy at producing weight loss across ADIs, with respective net differences of -10.6% (CI, -15.2% to -5.9%) for high ADI and -13.3% (CI, -15.7% to -10.9%) for low ADI. The interaction between ADI and intervention group was not significant for either HbA1c (P = 0.37) or weight loss (P = 0.31). Small sample size; parent trials were not designed to address effect modification by ADI. Surgery was superior to medical therapy for people with T2D regardless of social deprivation. This study did not detect statistically significant differences in the comparative advantage of surgery over medical therapy by ADI. National Institutes of Health.
- 4 February 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (4) , 537-545
Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study
OBJECTIVE: Type 2 diabetes and obesity are associated with reduced health-related quality of life (HRQoL) and health utility (HU), but long-term effects of metabolic/bariatric surgery (MBS) compared with those of medical/lifestyle intervention (MLI) on these outcomes are unclear. RESEARCH DESIGN AND METHODS: We studied 228 individuals with type 2 diabetes and obesity randomly assigned to MBS (Roux-en-Y gastric bypass, sleeve gastrectomy, or gastric band; n = 152) or MLI (n = 76) in the ARMMS-T2D study. HRQoL (36-Item Short-Form Health Survey [SF-36], including Physical Component Score [PCS] and Mental Component Score [MCS]) and HU (Short Form 6 Dimensions [SF-6D]) were measured annually up to 12 years. RESULTS: At baseline, participants’ mean ± SD age was 49.2 ± 8.0 years, 68.4% were female, BMI was 36.3 ± 3.4 kg/m2, and HbA1c was 8.7 ± 1.6%. PCS improved significantly more in the MBS versus MLI group over 12 years (+2.37 ± 0.53 vs. −0.95 ± 0.73; difference 3.32 ± 0.85; P < 0.001). MBS was associated with better general health (P < 0.001), physical functioning (P = 0.001), and vitality (P = 0.003). Reduction in BMI was greater after MBS versus MLI (P < 0.001) and correlated with improved PCS (r = −0.43; P < 0.001). Change in PCS was not associated with change in HbA1c. MCS changed minimally from baseline and was similar between MBS and MLI groups during follow-up (−0.21 ± 0.61 vs. −0.89 ± 0.84; difference 0.68 ± 0.97; P = 0.48). Improvements in HU were greater in the MBS versus MLI group over 12 years (+0.02 ± 0.01 vs. −0.01 ± 0.01; difference 0.03 ± 0.01; P = 0.003). CONCLUSIONS: Metabolic surgery produces sustained weight loss and improves PCS, general health, physical functioning, vitality, and HU in individuals with type 2 diabetes and obesity compared with medical therapy up to 12 years after intervention.
- 4 February 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (4) , 537-545
Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study
OBJECTIVE: Type 2 diabetes and obesity are associated with reduced health-related quality of life (HRQoL) and health utility (HU), but long-term effects of metabolic/bariatric surgery (MBS) compared with those of medical/lifestyle intervention (MLI) on these outcomes are unclear. RESEARCH DESIGN AND METHODS: We studied 228 individuals with type 2 diabetes and obesity randomly assigned to MBS (Roux-en-Y gastric bypass, sleeve gastrectomy, or gastric band; n = 152) or MLI (n = 76) in the ARMMS-T2D study. HRQoL (36-Item Short-Form Health Survey [SF-36], including Physical Component Score [PCS] and Mental Component Score [MCS]) and HU (Short Form 6 Dimensions [SF-6D]) were measured annually up to 12 years. RESULTS: At baseline, participants’ mean ± SD age was 49.2 ± 8.0 years, 68.4% were female, BMI was 36.3 ± 3.4 kg/m2, and HbA1c was 8.7 ± 1.6%. PCS improved significantly more in the MBS versus MLI group over 12 years (+2.37 ± 0.53 vs. −0.95 ± 0.73; difference 3.32 ± 0.85; P < 0.001). MBS was associated with better general health (P < 0.001), physical functioning (P = 0.001), and vitality (P = 0.003). Reduction in BMI was greater after MBS versus MLI (P < 0.001) and correlated with improved PCS (r = −0.43; P < 0.001). Change in PCS was not associated with change in HbA1c. MCS changed minimally from baseline and was similar between MBS and MLI groups during follow-up (−0.21 ± 0.61 vs. −0.89 ± 0.84; difference 0.68 ± 0.97; P = 0.48). Improvements in HU were greater in the MBS versus MLI group over 12 years (+0.02 ± 0.01 vs. −0.01 ± 0.01; difference 0.03 ± 0.01; P = 0.003). CONCLUSIONS: Metabolic surgery produces sustained weight loss and improves PCS, general health, physical functioning, vitality, and HU in individuals with type 2 diabetes and obesity compared with medical therapy up to 12 years after intervention.
- 12 September 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (12) , 6055-6061
Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
- 12 September 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (12) , 6055-6061
Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
- Open Access
- 12 September 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (21)
Postprandial metabolomics analysis reveals disordered serotonin metabolism in post-bariatric hypoglycemia
BACKGROUND: Bariatric surgery is a potent therapeutic approach for obesity and type 2 diabetes but can be complicated by post-bariatric hypoglycemia (PBH). PBH typically occurs 1–3 hours after meals, in association with exaggerated postprandial levels of incretins and insulin. METHODS: To identify mediators of disordered metabolism in PBH, we analyzed the plasma metabolome in the fasting state and 30 and 120 minutes after mixed meal in 3 groups: PBH ( n = 13), asymptomatic post–Roux-en-Y gastric bypass (post-RYGB) ( n = 10), and nonsurgical controls ( n = 8). RESULTS: In the fasting state, multiple tricarboxylic acid cycle intermediates and the ketone β-hydroxybutyrate were increased by 30%–80% in PBH versus asymptomatic. Conversely, multiple amino acids (branched-chain amino acids, tryptophan) and polyunsaturated lipids were reduced by 20%–50% in PBH versus asymptomatic. Tryptophan-related metabolites, including kynurenate, xanthurenate, and serotonin, were reduced 2- to 10-fold in PBH in the fasting state. Postprandially, plasma serotonin was uniquely increased 1.9-fold in PBH versus asymptomatic post-RYGB. In mice, serotonin administration lowered glucose and increased plasma insulin and GLP-1. Moreover, serotonin-induced hypoglycemia in mice was blocked by the nonspecific serotonin receptor antagonist cyproheptadine and the specific serotonin receptor 2 antagonist ketanserin. CONCLUSION: Together these data suggest that increased postprandial serotonin may contribute to the pathophysiology of PBH and provide a potential therapeutic target. FUNDING: National Institutes of Health (NIH) grant R01-DK121995, NIH grant P30-DK036836 (Diabetes Research Center grant, Joslin Diabetes Center), and Fundação de Amparo à Pesquisa do Estado de São Paulo grant 2018/22111-2.
- 12 September 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (21)
Open AccessPostprandial metabolomics analysis reveals disordered serotonin metabolism in post-bariatric hypoglycemia
BACKGROUND: Bariatric surgery is a potent therapeutic approach for obesity and type 2 diabetes but can be complicated by post-bariatric hypoglycemia (PBH). PBH typically occurs 1–3 hours after meals, in association with exaggerated postprandial levels of incretins and insulin. METHODS: To identify mediators of disordered metabolism in PBH, we analyzed the plasma metabolome in the fasting state and 30 and 120 minutes after mixed meal in 3 groups: PBH ( n = 13), asymptomatic post–Roux-en-Y gastric bypass (post-RYGB) ( n = 10), and nonsurgical controls ( n = 8). RESULTS: In the fasting state, multiple tricarboxylic acid cycle intermediates and the ketone β-hydroxybutyrate were increased by 30%–80% in PBH versus asymptomatic. Conversely, multiple amino acids (branched-chain amino acids, tryptophan) and polyunsaturated lipids were reduced by 20%–50% in PBH versus asymptomatic. Tryptophan-related metabolites, including kynurenate, xanthurenate, and serotonin, were reduced 2- to 10-fold in PBH in the fasting state. Postprandially, plasma serotonin was uniquely increased 1.9-fold in PBH versus asymptomatic post-RYGB. In mice, serotonin administration lowered glucose and increased plasma insulin and GLP-1. Moreover, serotonin-induced hypoglycemia in mice was blocked by the nonspecific serotonin receptor antagonist cyproheptadine and the specific serotonin receptor 2 antagonist ketanserin. CONCLUSION: Together these data suggest that increased postprandial serotonin may contribute to the pathophysiology of PBH and provide a potential therapeutic target. FUNDING: National Institutes of Health (NIH) grant R01-DK121995, NIH grant P30-DK036836 (Diabetes Research Center grant, Joslin Diabetes Center), and Fundação de Amparo à Pesquisa do Estado de São Paulo grant 2018/22111-2.
- 27 February 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (12) , e2261-e2272
Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine
Context Glycemic variability and hypoglycemia during diabetes treatment may impact therapeutic effectiveness and safety, even when glycated hemoglobin (HbA1c) reduction is comparable between therapies. Objective We employed masked continuous glucose monitoring (CGM) during a randomized trial of dapagliflozin plus saxagliptin (DAPA+SAXA) vs insulin glargine (INS) to compare glucose variability and patient-reported outcomes (PROs). Design 24-week sub-study of a randomized, open-label, two-arm, parallel-group, phase 3b study. Setting Multicenter study (112 centers in 11 countries). Patients 283 adults with type 2 diabetes (T2D) inadequately controlled with metformin ± sulfonylurea. Interventions DAPA+SAXA vs INS. Main outcome measures Changes in CGM profiles, HbA1c, and PROs. Results Changes from baseline in HbA1c with DAPA+SAXA were similar to those observed with INS, with mean difference [95% CI] between decreases of −0.12% [−0.37 to 0.12%], P = .33. CGM analytics were more favorable for DAPA+SAXA, including greater percent time in range (> 3.9 and ≤ 10 mmol/L; 34.3 ± 1.9 vs 28.5 ± 1.9%, P = .033), lower percent time with nocturnal hypoglycemia (area under the curve ≤ 3.9 mmol/L; 0.6 ± 0.5 vs 2.7 ± 0.5%, P = .007), and smaller mean amplitude of glycemic excursions (−0.7 ± 0.1 vs −0.3 ± 0.1 mmol/L, P = .017). Improvements in CGM were associated with greater satisfaction, better body weight image, less weight interference, and improved mental and emotional well-being. Conclusions DAPA+SAXA and INS were equally effective in reducing HbA1c at 24 weeks, but people with T2D treated with DAPA+SAXA achieved greater time in range, greater reductions in glycemic excursions and variability, less time with hypoglycemia, and improved patient-reported health outcomes.
- 27 February 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (12) , e2261-e2272
Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine
Context Glycemic variability and hypoglycemia during diabetes treatment may impact therapeutic effectiveness and safety, even when glycated hemoglobin (HbA1c) reduction is comparable between therapies. Objective We employed masked continuous glucose monitoring (CGM) during a randomized trial of dapagliflozin plus saxagliptin (DAPA+SAXA) vs insulin glargine (INS) to compare glucose variability and patient-reported outcomes (PROs). Design 24-week sub-study of a randomized, open-label, two-arm, parallel-group, phase 3b study. Setting Multicenter study (112 centers in 11 countries). Patients 283 adults with type 2 diabetes (T2D) inadequately controlled with metformin ± sulfonylurea. Interventions DAPA+SAXA vs INS. Main outcome measures Changes in CGM profiles, HbA1c, and PROs. Results Changes from baseline in HbA1c with DAPA+SAXA were similar to those observed with INS, with mean difference [95% CI] between decreases of −0.12% [−0.37 to 0.12%], P = .33. CGM analytics were more favorable for DAPA+SAXA, including greater percent time in range (> 3.9 and ≤ 10 mmol/L; 34.3 ± 1.9 vs 28.5 ± 1.9%, P = .033), lower percent time with nocturnal hypoglycemia (area under the curve ≤ 3.9 mmol/L; 0.6 ± 0.5 vs 2.7 ± 0.5%, P = .007), and smaller mean amplitude of glycemic excursions (−0.7 ± 0.1 vs −0.3 ± 0.1 mmol/L, P = .017). Improvements in CGM were associated with greater satisfaction, better body weight image, less weight interference, and improved mental and emotional well-being. Conclusions DAPA+SAXA and INS were equally effective in reducing HbA1c at 24 weeks, but people with T2D treated with DAPA+SAXA achieved greater time in range, greater reductions in glycemic excursions and variability, less time with hypoglycemia, and improved patient-reported health outcomes.
- 6 December 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (4) , e1370
Response to Letter to Editor From Tayek and Umpierrez: “New Onset or Stress Hyperglycemia and Mortality Risk”
Tayek and Umpierrez ask 2 questions. The first is whether the importance of relative hyperglycemia, as measured by the glycemic gap ( 1), depends on the presence of diabetes prehospital admission. They note as previously observed by others, hyperglycemia during illness in those without established diabetes, or “stress hyperglycemia (SH),” was found to be associated with up to a 5-fold higher mortality rate than in those presenting with the same degree of hyperglycemia in the setting of previously established diabetes ( 2-4). The authors’ second question is whether the observation of increased mortality in SH reflects new- or recent-onset diabetes, whereby hyperglycemia occurring either shortly before or at the onset of illness may be promoting worse outcomes. The lack of detailed blood glucose measurements from 3 months prior to hospitalization has led to conflicting findings in the literature ( 5). While we do not have these data due to the retrospective nature of the study, our population is unique in that each individual (N = 1786) had a recent glycated hemoglobin A1c available either from the ambulatory setting in the last 3 months or obtained at admission. Our cohort included individuals with preexisting diabetes (91.4% of cohort), defined as having a diabetes diagnosis on their problem list (82.0%) or A1c greater than 6.4% (9.5%), suggesting that the majority were not newly dysglycemic on admission. Importantly, while SH (glucose >180 mg/dL twice within 24 hours at any time during admission) did not drive our results given the low prevalence (8.6%), all SH patients would have a high glycemic gap by definition. Hence, our results overall support the existing SH literature but also identify higher risk in those with preexisting diabetes presenting with greater degrees of acute glycemic dysregulation.
- 6 December 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (4) , e1370
Response to Letter to Editor From Tayek and Umpierrez: “New Onset or Stress Hyperglycemia and Mortality Risk”
Tayek and Umpierrez ask 2 questions. The first is whether the importance of relative hyperglycemia, as measured by the glycemic gap ( 1), depends on the presence of diabetes prehospital admission. They note as previously observed by others, hyperglycemia during illness in those without established diabetes, or “stress hyperglycemia (SH),” was found to be associated with up to a 5-fold higher mortality rate than in those presenting with the same degree of hyperglycemia in the setting of previously established diabetes ( 2-4). The authors’ second question is whether the observation of increased mortality in SH reflects new- or recent-onset diabetes, whereby hyperglycemia occurring either shortly before or at the onset of illness may be promoting worse outcomes. The lack of detailed blood glucose measurements from 3 months prior to hospitalization has led to conflicting findings in the literature ( 5). While we do not have these data due to the retrospective nature of the study, our population is unique in that each individual (N = 1786) had a recent glycated hemoglobin A1c available either from the ambulatory setting in the last 3 months or obtained at admission. Our cohort included individuals with preexisting diabetes (91.4% of cohort), defined as having a diabetes diagnosis on their problem list (82.0%) or A1c greater than 6.4% (9.5%), suggesting that the majority were not newly dysglycemic on admission. Importantly, while SH (glucose >180 mg/dL twice within 24 hours at any time during admission) did not drive our results given the low prevalence (8.6%), all SH patients would have a high glycemic gap by definition. Hence, our results overall support the existing SH literature but also identify higher risk in those with preexisting diabetes presenting with greater degrees of acute glycemic dysregulation.
- Open Access
- 5 October 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (Supplement)
OR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?
Disclosure: A. Grover: None. A.L. Sheehan: None. C. Cummings: None. M. Farahmandsadr: None. H. Saeed: None. A.M. Puleio: None. D.C. Simonson: Stock Owner; Self; Phase V Technologies, GI Windows. M. Patti: Consulting Fee; Self; AstraZeneca, MBX-Biosciences, Hanmi Pharmaceutical. Other; Self; DSMB: Fractyl Health, Inc. Introduction: Post-bariatric hypoglycemia (PBH) is a severe, disabling complication of Roux-en-Y gastric bypass (RYGB). We aimed to identify clinical characteristics distinguishing patients with severe PBH vs. post-RYGB patients without symptomatic hypoglycemia (RYGB non-hypo) to help elucidate PBH pathophysiology and potential risk factors. Methods: Adults aged 18-70, without diabetes mellitus (DM), were recruited into 3 groups: (1) PBH with neuroglycopenia (n=33); (2) RYGB non-hypo (n=16); (3) non-surgical weight-matched controls (n=17). Detailed history of hypoglycemia, medical/surgical/family history, medications, Dumping Symptom Rating Scale (DSRS), and Rome IV diagnostic criteria for Irritable Bowel Syndrome (IBS) was completed. Differences between PBH and RYGB non-hypo were evaluated by unpaired t-tests and chi-square analysis as indicated. Results: PBH participants were 90% female, mean age 53±2 y, BMI 32±1 kg/m2, 39±2% body fat, with similar data for RYGB non-hypo (100% female, age 54±2 y, BMI 33±2 kg/m2, 40±2% fat), and controls (65% female, age 45±4 y, BMI 31±2 kg/m2, 35±3% fat). 90% of PBH reported level 3 hypoglycemia, with ER visits in 29% and motor vehicle accidents in 7%. Reduced awareness of hypoglycemia was reported by 80% of PBH, with hypoglycemia awareness at mean glucose of 57±2 mg/dL. 29% of PBH reported hypoglycemic symptoms occurring preoperatively, and 20% reported family history of hypoglycemia. The majority of PBH reported depression, change in driving habits, and adverse impact on employment. When compared with RYGB non-hypo, PBH participants had no difference in postoperative weight loss trajectories but had higher prevalence of revisional surgeries (pConclusion: PBH participants reported high rates of hypoglycemia unawareness, a likely contributor to hypoglycemia severity, recurrence, and adverse effects on safety and personal life. High rates of IBS, dumping symptoms, and orthostatic hypotension suggest possible disordered autonomic regulation in the pathophysiology of PBH. Self-reported preoperative symptoms and family history of hypoglycemia suggest possible differences in glucose metabolism prior to surgery in at-risk individuals. Preoperative assessment of these and other factors, together with longitudinal follow-up studies to determine incidence of PBH, will be required to identify risk factors for development of post-bariatric hypoglycemia. Presentation: Sunday, June 18, 2023
- 5 October 2023
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (Supplement)
Open AccessOR34-03 Defining Clinical Characteristics Of Patients With Severe Hypoglycemia After Roux-en-Y Gastric Bypass: How Do They Differ From Asymptomatic Patients?
Disclosure: A. Grover: None. A.L. Sheehan: None. C. Cummings: None. M. Farahmandsadr: None. H. Saeed: None. A.M. Puleio: None. D.C. Simonson: Stock Owner; Self; Phase V Technologies, GI Windows. M. Patti: Consulting Fee; Self; AstraZeneca, MBX-Biosciences, Hanmi Pharmaceutical. Other; Self; DSMB: Fractyl Health, Inc. Introduction: Post-bariatric hypoglycemia (PBH) is a severe, disabling complication of Roux-en-Y gastric bypass (RYGB). We aimed to identify clinical characteristics distinguishing patients with severe PBH vs. post-RYGB patients without symptomatic hypoglycemia (RYGB non-hypo) to help elucidate PBH pathophysiology and potential risk factors. Methods: Adults aged 18-70, without diabetes mellitus (DM), were recruited into 3 groups: (1) PBH with neuroglycopenia (n=33); (2) RYGB non-hypo (n=16); (3) non-surgical weight-matched controls (n=17). Detailed history of hypoglycemia, medical/surgical/family history, medications, Dumping Symptom Rating Scale (DSRS), and Rome IV diagnostic criteria for Irritable Bowel Syndrome (IBS) was completed. Differences between PBH and RYGB non-hypo were evaluated by unpaired t-tests and chi-square analysis as indicated. Results: PBH participants were 90% female, mean age 53±2 y, BMI 32±1 kg/m2, 39±2% body fat, with similar data for RYGB non-hypo (100% female, age 54±2 y, BMI 33±2 kg/m2, 40±2% fat), and controls (65% female, age 45±4 y, BMI 31±2 kg/m2, 35±3% fat). 90% of PBH reported level 3 hypoglycemia, with ER visits in 29% and motor vehicle accidents in 7%. Reduced awareness of hypoglycemia was reported by 80% of PBH, with hypoglycemia awareness at mean glucose of 57±2 mg/dL. 29% of PBH reported hypoglycemic symptoms occurring preoperatively, and 20% reported family history of hypoglycemia. The majority of PBH reported depression, change in driving habits, and adverse impact on employment. When compared with RYGB non-hypo, PBH participants had no difference in postoperative weight loss trajectories but had higher prevalence of revisional surgeries (pConclusion: PBH participants reported high rates of hypoglycemia unawareness, a likely contributor to hypoglycemia severity, recurrence, and adverse effects on safety and personal life. High rates of IBS, dumping symptoms, and orthostatic hypotension suggest possible disordered autonomic regulation in the pathophysiology of PBH. Self-reported preoperative symptoms and family history of hypoglycemia suggest possible differences in glucose metabolism prior to surgery in at-risk individuals. Preoperative assessment of these and other factors, together with longitudinal follow-up studies to determine incidence of PBH, will be required to identify risk factors for development of post-bariatric hypoglycemia. Presentation: Sunday, June 18, 2023
- Open Access
- 3 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (8) , 2191-2202
Continuous glucose monitoring in patients with post‐bariatric hypoglycaemia reduces hypoglycaemia and glycaemic variability
Aim: To determine whether continuous glucose monitoring (CGM) can reduce hypoglycaemia in patients with post‐bariatric hypoglycaemia (PBH). Materials and Methods: In an open‐label, nonrandomized, pre‐post design with sequential assignment, CGM data were collected in 22 individuals with PBH in two sequential phases: (i) masked (no access to sensor glucose or alarms); and (ii) unmasked (access to sensor glucose and alarms for low or rapidly declining sensor glucose). Twelve participants wore the Dexcom G4 device for a total of 28 days, while 10 wore the Dexcom G6 device for a total of 20 days. Results: Participants with PBH spent a lower percentage of time in hypoglycaemia over 24 hours with unmasked versus masked CGM (P = 0.03; P = 0.02). Conclusions: Real‐time CGM data and alarms are associated with reductions in low sensor glucose, elevated sensor glucose, and glycaemic variability. This suggests CGM allows patients to detect hyperglycaemic peaks and imminent hypoglycaemia, allowing dietary modification and self‐treatment to reduce hypoglycaemia. The use of CGM devices may improve safety in PBH, particularly for patients with hypoglycaemia unawareness.
- 3 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (8) , 2191-2202
Open AccessContinuous glucose monitoring in patients with post‐bariatric hypoglycaemia reduces hypoglycaemia and glycaemic variability
Aim: To determine whether continuous glucose monitoring (CGM) can reduce hypoglycaemia in patients with post‐bariatric hypoglycaemia (PBH). Materials and Methods: In an open‐label, nonrandomized, pre‐post design with sequential assignment, CGM data were collected in 22 individuals with PBH in two sequential phases: (i) masked (no access to sensor glucose or alarms); and (ii) unmasked (access to sensor glucose and alarms for low or rapidly declining sensor glucose). Twelve participants wore the Dexcom G4 device for a total of 28 days, while 10 wore the Dexcom G6 device for a total of 20 days. Results: Participants with PBH spent a lower percentage of time in hypoglycaemia over 24 hours with unmasked versus masked CGM (P = 0.03; P = 0.02). Conclusions: Real‐time CGM data and alarms are associated with reductions in low sensor glucose, elevated sensor glucose, and glycaemic variability. This suggests CGM allows patients to detect hyperglycaemic peaks and imminent hypoglycaemia, allowing dietary modification and self‐treatment to reduce hypoglycaemia. The use of CGM devices may improve safety in PBH, particularly for patients with hypoglycaemia unawareness.
- 25 October 2022
- Published by National Association of Teachers of Singing, Inc in journal of Singing
- Vol. 79 (2) , 263-264
Recent Research in Singing
RECENT RESEARCH IN SINGING
- 25 October 2022
- Published by National Association of Teachers of Singing, Inc in journal of Singing
- Vol. 79 (2) , 263-264
Recent Research in Singing
RECENT RESEARCH IN SINGING